Aldosterone synthase inhibition in humans

Nephrology Dialysis Transplantation

Volumn 28, Issue 1, 2013, Pages 36-43

  Azizi, Michel ^a,b,c   Amar, Laurence ^a,b,c   Menard, Joël ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

aldosterone; enzyme; human; hypertension; inhibitors

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; AMINOGLUTETHIMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN; CORTODOXONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FAD 286; FAD 286A; FADROZOLE; HYDROCORTISONE; LCI 699; METYRAPONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXIDOREDUCTASE INHIBITOR; PLACEBO; RENIN; SPIRONOLACTONE; TRILOSTANE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONGESTIVE HEART FAILURE; CORTICOTROPIN BLOOD LEVEL; DEHYDRATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEINURIA; SEXUAL DYSFUNCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANTIHYPERTENSIVE AGENTS; ENZYME INHIBITORS; HUMANS; HYPERTENSION; IMIDAZOLES; PYRIDINES; STEROID 11-BETA-HYDROXYLASE;

EID: 84872240598     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs388     Document Type: Article

References (60)

1. Conn JW. Primary aldosteronism. J Lab Clin Med 1955; 45: 661-664
2. Mulatero P, Stowasser M, Loh KC et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050
3. Connell JM, MacKenzie SM, Freel EM et al. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocr Rev 2008; 29: 133-154
4. Laragh JH, Ulick S, Januszewicz V et al. Electrolyte metabolism and aldosterone secretion in benign and malignant hypertension. Ann Intern Med 1960; 53: 259-272
5. Guyton AC, Coleman TG, Cowley AV, Jr. et al. Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 1972; 52: 584-594
6. Williams ED, Boddy K, Brown JJ et al. Body elemental composition, with particular reference to total and exchangeable sodium and potassium and total chlorine, in untreated and treated primary hyperaldosteronism. J Hypertens 1984; 2: 171-176
7. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005; 14: 235-241
8. Funder JW, Mihailidou AS. Aldosterone and mineralocorticoid receptors: clinical studies and basic biology. Mol Cell Endocrinol 2009; 301: 2-6
9. Rossi GP, Bernini G, Desideri G et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-238
10. Newton-Cheh C, Guo CY, Gona P et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49: 846-856
11. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
12. Meneton P, Galan P, Bertrais S et al. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged caucasian populations. J Hum Hypertens 2008; 22: 550-558
13. Calhoun DA, Nishizaka MK, Zaman MA et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
14. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168: 1159-1164
15. Bentley-Lewis R, Adler GK, Perlstein T et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92: 4472-4475
16. Garg R, Hurwitz S, Williams GH et al. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab 2010; 95: 1986-1990
17. Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1235
18. Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol 2004; 217: 67-74
19. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006; 47: 312-318
20. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011; 13: 163-172
21. Hobler A, Kagawa N, Hutter MC et al. Human aldosterone synthase: recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level. J Steroid Biochem Mol Biol 2012, doi:10.1016/j. jsbmb.2012.03.002
22. Bureik M, Lisurek M, Bernhardt R. The human steroid hydroxylases CYP1B1 and CYP11B2. Biol Chem 2002; 383: 1537-1551
23. Takeda Y, Zhu A, Yoneda T et al. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2007; 20: 1119-1124
24. Hattangady NG, Olala LO, Bollag WB et al. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2012; 350: 151-162
25. Bassett MH, Mayhew B, Rehman K et al. Expression profiles for steroidogenic enzymes in adrenocortical disease. J Clin Endocrinol Metab 2005; 90: 5446-5455
26. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004; 217: 45-52
27. Jansen PM, Danser AH, Imholz BP et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27: 680-691
28. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717
29. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
30. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
31. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442
32. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68
33. Epstein M, Williams GH, Weinberger M et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
34. Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650
35. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9
36. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001; 19: 353-361
37. Parthasarathy HK, Menard J, White WB et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29: 980-990
38. Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 2007; 116: 268-275
39. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839-845
40. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2: 462-468
41. Vaclavik J, Sedlak R, Plachy M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075
42. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-1838
43. Jeunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825
44. Weinberger MH, Roniker B, Krause SL et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716
45. Menard J, Gonzalez MF, Guyene TT et al. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24: 1147-1155
46. Orth DN, Kowacs WJ, DeBold CR. The adrenal cortex. In: Wilson JD, Foster DW (eds). Williams Texbook of Endocrinology. Philadelphia: WB Saunders, 1992, pp. 489-620
47. Menard J, Watson C, Rebello S et al. Hormonal and electrolyte responses to the aldosterone synthase inhibitor lci699 in sodium depleted healthy subjects. J Am Coll Cardiol 2010; 55: A61.E583
48. Amar L, Azizi M, Menard J et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010; 56: 831-838
49. Calhoun DA, White WB, Krum H et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo-and active-controlled phase 2 trial. Circulation 2011; 124: 1945-1955
50. Lamberts SW, Bruining HA, Marzouk H et al. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 1989; 69: 896-901
51. Demers LM, Melby JC, Wilson TE et al. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab 1990; 70: 1162-1166
52. Trunet PF, Mueller P, Girard F et al. The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 1992; 74: 571-576
53. Menard J, Pascoe L. Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosteronesynthase inhibition? J Hypertens 2006; 24: 993-997
54. LaSala D, Shibanaka Y, Jeng AY. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal Biochem 2009; 394: 56-61
55. Fiebeler A, Nussberger J, Shagdarsuren E et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111: 3087-3094
56. Mulder P, Mellin V, Favre J et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008; 29: 2171-2179
57. Lea WB, Kwak ES, Luther JM et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944
58. Boulkroun S, Samson-Couterie B, Dzib JF et al. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010; 56: 885-892
59. Zimmer C, Hafner M, Zender M et al. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg Med Chem Lett 2011; 21: 186-190
60. Fagart J, Hillisch A, Huyet J et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 2010; 285: 29932-29940